Dr. Kari Nadeau is the Naddisy Foundation Endowed Professor of Medicine and Pediatrics and Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She is Section Chief in Asthma and Allergy in the Pulmonary, Allergy, and Critical Care Division at Stanford, and she is now the Sr. Director of Clinical Research for the Division of Hospital Medicine.
For more than 30 years, Dr. Nadeau has devoted herself to understanding how environmental and genetic factors affect the risk of developing allergies and asthma, and the molecular mechanisms underlying the diseases. She has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanism of new therapies and then translating them clinically to make transformative changes in patients. She has led research in oncology, transplant, and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH. She started four biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval.
Dr. Nadeau received her M.D. and Ph.D. from Harvard Medical School through the NIH MSTP program scholarships. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and at University of California, San Francisco.
Dr. Nadeau has served as an FDA consultant and a reviewer for NIH Study Sections. She is currently a Fellow in the American Academy of Allergy, Asthma, and Immunology (AAAAI), and she serves on the National Scientific Committee for the Immune Tolerance Network (ITN) of the National Institute of Allergy and Infectious Disease (NIAID). Dr. Nadeau contributes on multiple editorial boards for high-impact journals and to date has published over 200 peer-reviewed publications.